Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.75 Insider Own14.94% Shs Outstand48.97M Perf Week-19.87%
Market Cap59.63M Forward P/E- EPS next Y-2.53 Insider Trans0.00% Shs Float41.92M Perf Month-33.15%
Income-134.92M PEG- EPS next Q-0.67 Inst Own73.66% Short Float / Ratio4.66% / 4.07 Perf Quarter-48.07%
Sales20.35M P/S2.93 EPS this Y-1.05% Inst Trans-2.11% Short Interest1.95M Perf Half Y-66.48%
Book/sh4.39 P/B0.28 EPS next Y4.33% ROA-33.97% Target Price17.00 Perf Year-85.39%
Cash/sh4.39 P/C0.28 EPS next 5Y22.30% ROE-50.51% 52W Range1.23 - 9.41 Perf YTD-79.49%
Dividend- P/FCF- EPS past 5Y-46.29% ROI-47.66% 52W High-87.14% Beta2.20
Dividend %- Quick Ratio7.39 Sales past 5Y17.88% Gross Margin60.35% 52W Low-1.63% ATR0.18
Employees146 Current Ratio7.39 Sales Q/Q63.93% Oper. Margin-687.49% RSI (14)32.43 Volatility16.51% 11.20%
OptionableYes Debt/Eq0.33 EPS Q/Q15.89% Profit Margin-663.05% Rel Volume9.02 Prev Close1.48
ShortableYes LT Debt/Eq0.31 EarningsNov 01 BMO Payout- Avg Volume479.84K Price1.21
Recom2.00 SMA20-27.11% SMA50-27.85% SMA200-59.46% Volume4,329,036 Change-18.24%
Date Action Analyst Rating Change Price Target Change
Feb-24-23Upgrade Credit Suisse Underperform → Neutral $12 → $10
Feb-24-23Downgrade JP Morgan Neutral → Underweight $15 → $5
Nov-04-22Downgrade JP Morgan Overweight → Neutral $22 → $15
Oct-11-22Initiated Morgan Stanley Underweight $6
Apr-28-22Initiated Credit Suisse Underperform $10
Apr-11-22Downgrade BofA Securities Buy → Neutral $46 → $15
Mar-10-22Initiated JP Morgan Overweight $43
Feb-11-22Resumed BMO Capital Markets Outperform $57
Feb-10-22Initiated Wells Fargo Equal Weight $25
Nov-23-21Initiated BofA Securities Buy $54
Nov-28-23 07:00AM
Nov-20-23 07:00AM
Nov-13-23 09:55AM
Nov-01-23 11:03AM
07:00AM Loading…
Oct-11-23 07:00AM
Sep-05-23 04:01PM
Aug-28-23 06:30PM
Aug-08-23 08:40AM
Aug-04-23 06:58AM
Jul-17-23 07:00AM
Jul-05-23 07:00AM
Jun-20-23 07:00AM
07:00AM Loading…
May-30-23 07:00AM
May-14-23 08:06AM
May-04-23 08:15AM
Apr-19-23 07:00AM
Apr-11-23 09:35AM
Mar-23-23 07:39AM
Feb-24-23 05:38AM
Feb-23-23 08:35AM
Feb-08-23 07:00AM
Jan-30-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 06:15PM
Jan-04-23 09:40AM
07:00AM Loading…
Jan-03-23 07:00AM
Nov-13-22 07:13AM
Nov-08-22 09:55AM
Nov-03-22 08:25AM
Nov-02-22 10:01AM
Oct-03-22 09:02AM
Sep-29-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 08:22AM
Aug-10-22 06:05AM
Aug-07-22 08:21AM
Aug-04-22 09:15AM
Aug-02-22 08:00AM
May-16-22 08:00AM
May-05-22 09:15AM
Apr-08-22 02:15PM
Mar-17-22 11:44AM
Mar-16-22 04:05PM
Mar-09-22 08:00AM
Mar-08-22 04:30PM
Feb-24-22 07:00AM
Feb-07-22 04:45AM
Jan-12-22 11:09AM
Jan-10-22 07:00AM
Jan-03-22 07:00AM
Dec-29-21 12:00PM
Dec-17-21 08:00AM
Dec-01-21 07:28AM
Nov-22-21 12:00PM
Nov-10-21 04:01PM
Oct-26-21 10:41AM
Oct-09-21 09:14AM
Sep-17-21 10:27AM
Aug-11-21 04:02PM
Aug-10-21 01:31AM
Jul-21-21 04:24AM
Jul-19-21 01:44PM
Jun-21-21 04:01PM
Jun-16-21 07:51PM
Jun-14-21 04:12PM
Jun-07-21 07:00AM
May-26-21 07:00AM
May-20-21 04:01PM
May-13-21 04:01PM
May-12-21 07:00AM
May-02-21 03:53AM
Apr-10-21 03:05PM
Mar-10-21 04:41PM
Mar-02-21 11:50PM
Feb-24-21 07:00AM
Feb-11-21 07:00AM
Jan-19-21 07:00AM
Jan-07-21 07:00AM
Jan-06-21 07:00AM
Dec-17-20 07:00AM
Nov-25-20 07:00AM
Nov-13-20 07:00AM
Nov-12-20 04:05PM
Oct-23-20 05:54PM
Oct-14-20 07:30AM
Oct-06-20 04:05PM
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Koppikar UtpalDirectorFeb 08Buy5.605,66731,7355,667Feb 10 04:27 PM
Anderson Kenneth CarlDirectorJan 06Option Exercise3.907122,77795,128Jan 06 04:55 PM